News

<!DOCTYPE html> <html lang="en"> <head> <title>News</title> <meta name="description" content="Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous), and PB357 in 2011. In 2022, Puma in-licensed global research and development and commercial rights to alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Neratinib is a potent irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4. Puma has been focused on developing the oral version of neratinib, and its most advanced drug candidates are directed at the treatment of HER2-positive breast cancer. Puma believes that neratinib has clinical applications in the treatment of several other cancers as well, including non-small cell lung cancer and other solid tumor types that over-express or have a mutation in HER2. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy. Puma commenced commercial sales of the drug in 2017 and it is marketed in the United States as NERLYNX® tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. Commercial sales commenced in the European Union in 2019. Puma has entered into additional exclusive license agreements with various parties to commercialize NERLYNX in regions outside the United States, including the European Union, Canada, Latin America, Greater China, Israel, Southeast Asia, Australia, New Zealand, South Korea, the Middle East, and parts of Africa. Puma plans to continue to pursue the commercialization of NERLYNX outside the United States. Alisertib is an adenosine triphosphate鈥揷ompetitive and reversible inhibitor of aurora kinase A and results in disruption of mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Alisertib has been tested in Clinical Trials in patients with metastatic cancers including breast cancer, small cell lung cancer, head and neck cancer, ovarian cancer, peripheral T cell lymphoma and acute myeloid leukemia. Puma initially intends to focus the development of alisertib on the treatment of patients with metastatic estrogen receptor-positive (ER-positive) HER2-negative breast cancer, triple-negative breast cancer and small cell lung cancer. Alan H. Auerbach has served as Chairman of the Board, CEO and President of Puma Biotechnology, Inc. since he founded the Company in 2010. Prior to Puma, Mr. Auerbach served as CEO, President and a Member of the Board of Directors of Cougar Biotechnology, Inc., from its inception in 2003 until its acquisition by Johnson & Johnson in July 2009. From July 2009 until January 2010, Mr. Auerbach served as Co-Chairman of the Integration Steering Committee at Cougar (as part of J&J), providing leadership and oversight for the development and global commercialization of Cougar's lead product candidate, abiraterone acetate. Abiraterone (Zytiga) was approved for the treatment of metastatic prostate cancer in the U.S. in April 2011 and in the EU in September 2011. Prior to founding Cougar, from June 1998 to April 2003 Mr. Auerbach was Vice President, Senior Research Analyst at Wells Fargo Securities, where he was responsible for research coverage of small- and mid-cap biotechnology companies, with a focus on oncology. He had primary responsibility for technical, scientific and clinical due diligence, and selected biotechnology companies followed by the company. In 2002, Mr. Auerbach ranked second in the NASDAQ/Starmine survey of analyst performance for stock picking in biotechnology. From August 1997 to May 1998, Mr. Auerbach was Vice President, Research Analyst at the Seidler Companies, Inc., where he was responsible for research coverage of small-cap biotechnology companies. Prior to his work as a securities analyst, Mr. Auerbach worked for Diagnostic Products Corporation, where he designed and implemented Clinical Trials in the field of oncology. Mr. Auerbach received a B.S. in Biomedical Engineering from Boston University and an M.S. in Biomedical Engineering from the University of Southern California. Puma Biotechnology, Inc., founded in 2010, is headquartered in Los Angeles, California. Additional information may be found at https://www.pumabiotechnology.com. NERLYNX® is a registered trademark of Puma Biotechnology, Inc." /> <meta name="keywords" content="Puma Biotechnology, biotechnology, nerlynx, neratinib, neratinib tablets, breast cancer, early stage, metastatic, drug development, pb272, Clinical Trials, oncology, her2+, biopharmaceutical, in-licensing, cancer treatment, oncology, extended adjuvant therapy, non-small cell lung cancer, biliary cancer, ExteNET, SUMMIT, FB-10 , CONTROL, NALA, tyrosine kinase inhibitor, TBCRC-022, HER2-mutated, EGFR, EGFR exon 18, EGFR exon 18-mutant, HER-Seq, alisertib, aurora kinase A, adenosine triphosphate鈥揷ompetitive and reversible inhibitor of aurora kinase A, inhibitor of aurora kinase A, disruption of mitosis, apoptosis of rapidly proliferating tumor cells, apoptosis of tumor cells, breast cancer, small cell lung cancer, head and neck cancer, ovarian cancer, peripheral T cell lymphoma, acute myeloid leukemia, metastatic estrogen receptor-positive (ER-positive) HER2-negative breast cancer, triple-negative breast cancer, HER2-negative breast cancer, ER-positive breast cancer" /> <meta name="author" content="Puma Biotechnology, Inc." /> <meta charset="UTF-8" /> <meta name="format-detection" content="telephone=no" /> <link rel="stylesheet" href="../css/style.min.css?_v=202409285658555" /> <link rel="shortcut icon" href="../favicon.ico" /> <meta name="viewport" content="width=device-width, initial-scale=1.0" /> <script async src="https://kit.fontawesome.com/ee8e128eea.js" crossorigin="anonymous"></script> </head>  <script async src="https://www.googletagmanager.com/gtag/js?id=G-CN3D3P6NW6"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-CN3D3P6NW6'); </script> <script> const PATH = '../img/'; </script> <body> <div class="wrapper"> <header class="header" data-lp> <div class="header__container"> <div class="header__content"> <a href="../index.html" class="header__logo"> <picture> <source srcset="../img/logo.webp" type="image/webp" /> <img src="../img/logo.png" data-no-lazy width="299" height="102" aria-label="Puma Biotechnology Logo" alt="Puma Biotechnology Logo" /> </picture> </a> <div class="header__menu menu"> <button type="button" class="menu__icon icon-menu" aria-label="Open menu button"><span></span></button> <nav class="menu__body"> <ul class="menu__list"> <li class="menu__item"><a href="../index.html" class="menu__link">Home</a></li> <li class="menu__item"> <a href="../about/overview.html" class="menu__link">About</a> <ul class="menu__sublist"> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="../about/overview.html">Overview</a> </li> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="../about/leadership.html">Leadership Team</a> </li> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="../about/bod.html">Board of Directors</a> </li> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="../about/cg.html">Corporate Governance</a> </li> </ul> </li> <li class="menu__item"> <a href="../product/product.html" class="menu__link">Product</a> </li> <li class="menu__item"> <a href="../pipeline/pipeline.html" class="menu__link">Pipeline</a> </li> <li class="menu__item"> <a href="../clinical-trials/clinincal_trials.html" class="menu__link">Clinical Trials</a> <ul class="menu__sublist"> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="../clinical-trials/alisca_lung1.html">ALISCA™-Lung1</a> </li> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="../clinical-trials/alisca_breast1.html">ALISCA™-Breast1</a> </li> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="../clinical-trials/cds.html">Clinical Data Sharing</a> </li> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="../clinical-trials/eap.html">Extended Access Program</a> </li> </ul> </li> <li class="menu__item"> <a href="news.html" class="menu__link">News</a> <ul class="menu__sublist"> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="latest_news.html">Latest News Release</a> </li> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="news-archive.html">Archives</a> </li> </ul> </li> <li class="menu__item"> <a href="../investors/events_webcasts.html" class="menu__link">Investors</a> <ul class="menu__sublist"> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="https://investor.pumabiotechnology.com/news-releases/" target="_blank">News Releases</a> </li> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="../investors/events_webcasts.html">Events and Webcasts</a> </li> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="https://investor.pumabiotechnology.com/sec-filings/all-filings/default.aspx" target="_blank">SEC Filings</a> </li> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="https://investor.pumabiotechnology.com/resources/investor-faqs/default.aspx" target="_blank">Investor FAQs</a> </li> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="https://investor.pumabiotechnology.com/stock-information/default.aspx" target="_blank">Stock Information</a> </li> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="https://investor.pumabiotechnology.com/stock-information/default.aspx#stock-historical" target="_blank">Stock Lookup</a> </li> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="https://investor.pumabiotechnology.com/resources/investor-email-alerts/default.aspx" target="_blank">Stock Alerts</a> </li> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="https://investor.pumabiotechnology.com/analyst-coverage/default.aspx" target="_blank">Analyst Coverage</a> </li> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="https://investor.pumabiotechnology.com/sec-filings/annual-reports-and-proxies/default.aspx" target="_blank">Annual Meeting</a> </li> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="https://investor.pumabiotechnology.com/sec-filings/all-filings/default.aspx" target="_blank">Legal Notices</a> </li> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="https://investor.pumabiotechnology.com/resources/investor-contacts/default.aspx" target="_blank">Contacts</a> </li> </ul> </li> <li class="menu__item"> <a href="../contacts/contacts.html" class="menu__link">Contacts</a> </li> <li class="menu__item"> <a href="#" class="menu__link" data-popup=".third-website" data-popup-redirect="https://phf.tbe.taleo.net/phf03/ats/careers/v2/jobSearch?act=redirectCwsV2&cws=37&org=PUMABIOTECH">Careers</a> </li> </ul> </nav> </div> </div> </div> </header> <main class="page page--trials"> <section class="page__hero hero"> <div class="hero__container"> <div class="hero__body"> <div class="hero__info"> <h3 class="hero__title">Our Mission</h3> <p class="hero__descr">Puma Biotechnology is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer.</p> </div> <div class="hero__bg-image"> <img src="../img/hero/hero_bg.png" data-no-lazy decoding="async" width="1440" height="697" alt="" /> </div> </div> </div> </section>  <section class="page__news news"> <div class="news__container"> <div class="news__top"> <h2 class="news__title title">News</h2> <div class="news__links"> <a href="news.html" class="news__link active">Latest News Releases</a> <a href="news-archive.html" class="news__link"> Archive</a> </div> </div> <div class="news__body"> <h2 class="news__title">News Releases</h2> <div class="news__top-row"> <div class="news__year">Year</div> <div class="news__name">News Releases</div> </div> <div class="news__columns" data-tabs> <div class="news__navigate" data-tabs-titles> <button type="button" class="news__nav-button _tab-active">2024</button> </div> <div class="news__content" data-tabs-body> <ul class="news__list"> <li><b>Nov. 20, 2024 - Puma Biotechnology Announces Initiation of ALISCATM-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer <a href="2024/20241120.html">Read</a></b></li> <li>Nov. 7, 2024 - Puma Biotechnology Reports Third Quarter 2024 Financial Results <a href="2024/20241107Q3.html">Read</a></li> <li>Nov. 5, 2024 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) <a href="2024/20241105IA.html">Read</a></li> <li>Oct. 24, 2024 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results <a href="2024/20241024.html">Read</a></li> <li>Sept. 3, 2024 - Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference <a href="2024/20240903.html">Read</a></li> <li>Aug. 6, 2024 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) <a href="2024/20240806IA.html">Read</a></li> <li>Aug. 1, 2024 - Puma Biotechnology Reports Second Quarter Financial Results <a href="2024/20240801Q2.html">Read</a></li> <li>July 18, 2024 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results <a href="2024/20240718.html">Read</a></li> <li>July 2, 2024 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) <a href="2024/20240702IA.html">Read</a></li> <li>June 7, 2024 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) <a href="2024/20240607IA.html">Read</a></li> <li>June 3, 2024 - Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer <a href="2024/20240603.html">Read</a></li> <li>June 2, 2024 - Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041) <a href="2024/20240602.html">Read</a></li> <li>May 28, 2024 - Puma Biotechnology to Join Russell 3000 Index <a href="2024/20240528.html">Read</a></li> <li>May 23, 2024 - Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting <a href="2024/20240523.html">Read</a></li> <li>May 2, 2024 - Puma Biotechnology Reports First Quarter Financial Results <a href="2024/20240502Q1.html">Read</a></li> <li>April 18, 2024 - Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results <a href="2024/20240418.html">Read</a></li> <li>April 3, 2024 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) <a href="2024/20240403IA.html">Read</a></li> <li>Mar. 20, 2024 - Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer <a href="2024/20240320.html">Read</a></li> <li>Feb. 29, 2024 - Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results <a href="2024/20240229Q4.html">Read</a></li> <li>Feb. 27, 2024 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) <a href="2024/20240227IA.html">Read</a></li> <li>Feb. 22, 2024 - Puma Biotechnology to Participate in a Panel Discussion at TD Cowen鈥檚 44th Annual Health Care Conference <a href="2024/20240222.html">Read</a></li> <li>Feb. 15, 2024 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results <a href="2024/20240215.html">Read</a></li> <li>Feb. 13, 2024 - Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer <a href="2024/20240213.html">Read</a></li> <li>Jan. 11, 2024 - Puma Biotechnology to Present at B. Riley Securities 4 th Annual Oncology Conference <a href="2024/20240111.html">Read</a></li> </ul> </div> </div> </div> </div> </section>  <button type="button" class="back-top" data-goto=".wrapper"> <div class="back-top__icon"><i class="fa-solid fa-arrow-up"></i></div> <span class="back-top__text">Back to top</span> </button> </main> <footer class="footer"> <div class="footer__container"> <div class="footer__top"> <div class="footer__info"> <a href="../index.html" class="footer__logo" ><picture ><source srcset="../img/logo.webp" type="image/webp" /> <img src="../img/logo.png" width="140" height="48" alt="Puma Biotechnology, Inc. Logo" /></picture ></a> <div class="footer__col"> <h3 class="footer__label">About Us</h3> <ul class="footer__menu"> <li class="footer__item-menu"><a href="../about/overview.html">Overview</a></li> <li class="footer__item-menu"><a href="../about/leadership.html">Leadership team</a></li> <li class="footer__item-menu"><a href="../about/bod.html">Board of Directors</a></li> <li class="footer__item-menu"><a href="../about/cg.html">Corporate Governance</a></li> </ul> </div> </div> <div class="footer__social"> <h3 class="footer__label">Get in touch</h3> <ul class="footer__social-list">  <li class="footer__social-item"> <a href="#" aria-label="Follow us on LinkedIn" data-popup=".third-website" data-popup-redirect="https://www.linkedin.com/company/puma-biotechnology-ltd" target="_blank"><i class="fa-brands fa-linkedin"></i></a> </li> </ul> </div> </div> <div class="footer__contacts" data-da=".footer__top, 768, 1"> <h3 class="footer__label">Contact</h3> <div class="footer__line"> <div class="footer__row"> <h4 class="footer__caption">Puma Biotechnology, Inc.</h4> <p> Los Angeles, California <br /> 424-248-6500 Main </p> </div> <div class="footer__row"> <h4 class="footer__caption">Medical Information:</h4> 1-844-MED-PUMA (1-844-633-7862), or <br /> <a href="mailto:medinfo@pumabiotechnology.com">medinfo@pumabiotechnology.com</a> </div> <div class="footer__row"> <h4 class="footer__caption">Business Development:</h4> <p> <a href="mailto:info@pumabiotechnology.com">info@pumabiotechnology.com</a> </p> </div> <div class="footer__row"> <h4 class="footer__caption">Investor Relations:</h4> <a href="mailto:ir@pumabiotechnology.com">ir@pumabiotechnology.com</a> </div> </div> </div> <div class="footer__bottom"> <p class="footer__copyright">© 2024 Puma Biotechnology, Inc.</p> <ul class="footer__menu footer__menu--row"> <li class="footer__item-menu"><a href="../privacy_policy.html">Privacy Policy</a></li> <li class="footer__item-menu"><a href="../wa_pp.html">WA Privacy Policy</a></li> <li class="footer__item-menu"><a href="../tos.html">Terms of Service</a></li> <li class="footer__item-menu"><a href="../data_rights_request.html">Data Rights Request</a></li> <li class="footer__item-menu"><a href="../legal_notice.html">Legal Notices</a></li> <li class="footer__item-menu"><a href="../site_map.html">Site Map</a></li> </ul> </div> </div> </footer> </div>  <div id="popup" aria-hidden="true" class="popup third-website"> <div class="popup__wrapper"> <div class="popup__content"> <button data-close type="button" class="popup__close">Close</button> <div class="popup__text"> <h3>NOTICE: You are leaving our website</h3> <p> When you click on the button below, you will leave our website and will enter a website maintained by a third party that is not related to Puma Biotechnology, Inc. We are providing a link to the third party's website solely as a convenience to you, because we believe that website may provide useful content. We are not, by referring or linking to the third party website, incorporating its contents into our own website. We do not endorse or guarantee, and we disclaim any responsibility for the content, products or services offered on that website; its performance or interaction with your computer; its security and privacy policies and practices; and any consequences that may result from visiting that website. </p> <p> By clicking on the button below, you acknowledge and agree to everything we say above. <a class="popup__go-back" href="https://www.linkedin.com/company/puma-biotechnology-ltd"><span>Continue</span></a> </p> <p> You can also click on the link below to return to the Puma Biotechnology, Inc. website. <a class="popup__go-back" href="../index.html"><span>Go Back</span></a> </p> </div> </div> </div> </div> <div aria-hidden="true" class="popup succes"> <div class="popup__wrapper"> <div class="popup__content"> <button data-close type="button" class="popup__close"> <svg width="20" height="20"> <use xlink:href="../img/icons/icons.svg#svg-close"></use> </svg> </button> <div class="popup__thanks"> <h2>Thank you!</h2> <p>Your message was sent.</p> </div> </div> </div> </div> <script src="../js/app.min.js"></script> </body> </html>

CINXE.COM

News